Compare CORT & AMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CORT | AMG |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | United States |
| Employees | 730 | 5600 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.0B |
| IPO Year | 2001 | N/A |
| Metric | CORT | AMG |
|---|---|---|
| Price | $89.23 | $342.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $96.50 | ★ $384.00 |
| AVG Volume (30 Days) | ★ 957.9K | 336.1K |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 0.01% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $761,407,000.00 | N/A |
| Revenue This Year | $26.08 | $11.98 |
| Revenue Next Year | $26.98 | $9.34 |
| P/E Ratio | ★ N/A | $14.55 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $199.59 |
| 52 Week High | $91.00 | $363.89 |
| Indicator | CORT | AMG |
|---|---|---|
| Relative Strength Index (RSI) | 80.68 | 58.52 |
| Support Level | $76.41 | $293.62 |
| Resistance Level | N/A | $363.89 |
| Average True Range (ATR) | 3.76 | 9.61 |
| MACD | -0.09 | -2.60 |
| Stochastic Oscillator | 94.20 | 35.03 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Affiliated Managers Group offers investment strategies to investors through its network of affiliates. The firm typically buys a majority interest in small to mid-size boutique asset managers, receiving a fixed percentage of revenue from these firms in return. Affiliates operate independently, with AMG providing strategic, operational, and technology support, as well as global distribution. At the end of December 2025, AMG's affiliate network—which includes firms like Abacus Capital and Pantheon dedicated to private markets (which accounted for 18% of AUM), AQR Capital and Capula Investment Management in liquid alternatives (28%), and Harding Loevner, Tweedy Browne, Parnassus, and Yacktman in equities, multi-asset, and bond strategies (54%)—had $813.3 billion in managed assets.